C3J Therapeutics Revenue, Growth & Competitor Profile

Company Profile & Annual Report for C3J Therapeutics

Access the complete profile.

C3J Therapeutics Fast Facts

Revenue	$10 - $100 million    See Exact Annual Revenue
Employees	10 - 100Exact Company Size
Primary Industry	5417 Scientific Research & Development Services
Address	5005 Mcconnell Ave Los Angeles, CA 90066

Note: Revenues for privately held companies are statistical evaluations.


C3J Therapeutics's Annual Report & Profile shows critical firmographic facts:

• What is the company's size? (Annual sales and employees)
  • C3J Therapeutics's annual revenues are $10 - $100 million (see exact revenue data)
• What industry is the company in?
  • C3J Therapeutics is classified as operating in the Scientific Research & Development Services industry, NAICS Code 5417.

C3J Therapeutics Annual Revenue and Growth Rate

C3J Therapeutics	Revenue Est. ($ Million)	Growth Rate (%)	# Employees
2023	$10 - $100 million Details in Premium Report
2022
2021
2020
2019

1-Year Growth Rate: 3-Year Growth Rate (CAGR):

Note: C3J Therapeutics's revenues are gauged from an analysis of company filings.

C3J Therapeutics's Income Statement (based on Industry Averages)

C3J Therapeutics P&L	$ Millions
Revenue (Sales)
Cost of Goods Sold
Gross Profit
Operating Expenses
Advertising
Salaries and wages
Other Operating Expenses
Total Operating Expenses
Operating Income
EBITDA
EBIT (Earnings Before Interest and Taxes)
Net Profit

Trademark Applications

Trademark applications show the products and services that C3J Therapeutics is developing and marketing. C3J Therapeutics doesn't have any recent trademark applications, indicating C3J Therapeutics is focusing on its existing business rather than expanding into new products and markets. Trademarks may include brand names, product names, logos and slogans.

Trademark	Date
ARMATA PHARMACEUTICALS Targeted, pathogen-specific antimicrobial pharmaceutical preparations for the treatment of bacterial and fungal mediated infectious diseases as well as microbial dysbiosis associated with human disease	01/29/2019
C3J THERAPEUTICS Targeted, pathogen-specific antimicrobial pharmaceutical preparations for the treatment of bacteria and fungal mediated diseases and disorders caused by microbial dysbiosis	10/12/2015

See all trademarks and details in the Full Report.

Market Share of C3J Therapeutics's Largest Competitors

A competitive analysis shows these companies are in the same general field as C3J Therapeutics, even though they may not compete head-to-head. These are the largest companies by revenue. However, they may not have the largest market share in this industry if they have diversified into other business lines. The "Competition" section of a business plan or investment memorandum would start by analyzing the information about these companies. Competitive advantage comes from offering better pricing or superior products/service.

Company	Headquarters	Revenue ($ MM)
LEIDOS	Denver, CO	100
NATIONAL TECHNOLOGY & ENGINEERING SOLUTIONS OF SANDIA	Albuquerque, NM	30
INC RESEARCH	Raleigh, NC	27
RESEARCH FOUNDATION FOR STATE UNIVERSITY OF NEW YORK	Albany, NY	17
FLUOR MARINE PROPULSION	West Mifflin, PA	15
SYNEOS HEALTH	Raleigh, NC	13
ILLUMINA	San Diego, CA	12
UT-BATTELLE	Oak Ridge, TN	11
PRA HOLDINGS	Raleigh, NC	11

Nearby Competitors

These companies are similar in business line and location to C3J Therapeutics. While some companies compete with neighboring businesses for customers, other companies may compete to attract skilled employees.

Company	Headquarters	Revenue ($ MM)
NOVASIGNAL	Los Angeles, CA	100
PUMA BIOTECHNOLOGY	Los Angeles, CA	84
SILVUS TECHNOLOGIES	Los Angeles, CA	82
ELLISON INSTITUTE	Los Angeles, CA	78
SOMATIS SENSOR SOLUTIONS	Los Angeles, CA	69
C3J THERAPEUTICS	Los Angeles, CA	55

Future Competition: C3J Therapeutics's Fastest Growing Competitors

These companies are in the same general field as C3J Therapeutics and are rapidly expanding. Companies may grow organically or through acquisition. In some cases apparently high growth rates may be caused by data that weren't available in previous years.

Company	Revenue ($ MM)